Charity and drug company work together to develop cure for Chagas’ diseaseBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b4084 (Published 06 October 2009) Cite this as: BMJ 2009;339:b4084
- Bob Roehr
- 1Washington, DC
The Drugs for Neglected Diseases initiative (DNDi) has entered into an agreement with a drug company to develop the first new compound in nearly 40 years to treat Chagas’ disease. An estimated eight million people are infected with the parasite that causes the disease, Trypanosoma cruzi, a third of whom will die of heart or intestinal disease if left untreated.
Chagas’ disease is endemic in Latin American and Caribbean countries, and migration patterns have spread it worldwide. About 300 000 people in the United States are thought to be infected with it (BMJ 2009;339:b2859, doi:10.1136/bmj.b2859).
In an agreement with the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial